---
title: "Zhuo Zhu Health Group turned a profit of HKD 7.11 million for the full year, and will not declare a dividend"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279343034.md"
description: "Zhuo Zhu Health Group announced its annual financial report for the year ended December 31 last year, reporting a net loss of HKD 7.114 million, a significant turnaround from a net profit of HKD 11.338 million in the same period of 2024. The loss per share was HKD 0.035, and no final dividend was declared. The group's revenue was HKD 110 million, an increase of 3.9%, with sales revenue from the health care business approximately HKD 100 million, up 18.2%. Gross profit was HKD 39.528 million, an increase of 16.1%, with a gross profit margin of 38.7%, down 0.7 percentage points. The pre-tax loss was HKD 6.66 million, while the pre-tax profit for the same period in 2024 was HKD 12.589 million"
datetime: "2026-03-17T00:43:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279343034.md)
  - [en](https://longbridge.com/en/news/279343034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279343034.md)
---

# Zhuo Zhu Health Group turned a profit of HKD 7.11 million for the full year, and will not declare a dividend

According to a report from Economic News Agency on the 17th, Zhuozhuo Health Group (06877) announced a net loss of HKD 7.114 million for the year ended December 31 last year, while the net profit for the same period in 2024 was HKD 11.338 million; the loss per share was 0.35 cents, and no final dividend was declared.

The group stated that revenue was HKD 110 million, an increase of 3.9%, of which the sales revenue from health products was approximately HKD 100 million, an increase of 18.2%; gross profit was HKD 39.528 million, an increase of 16.1%; gross profit margin was 38.7%, a decrease of 0.7 percentage points; pre-tax loss was HKD 6.66 million, while the pre-tax profit for the same period in 2024 was HKD 12.589 million. (wh)

\\\* For details regarding the performance, please refer to the company's official announcement

### Related Stocks

- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [01889.HK](https://longbridge.com/en/quote/01889.HK.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial](https://longbridge.com/en/news/288238438.md)
- [China closing in but US still leads in biotech innovation, survey finds](https://longbridge.com/en/news/290431706.md)
- [Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial](https://longbridge.com/en/news/288172168.md)
- [Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 | SMMT Stock News](https://longbridge.com/en/news/288144694.md)